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Brain metastases remain a major problem in NSCLC. Major improvements in systemic therapies have
been observed during the past decade but their impact on brain metastases control as well as their
combination with radiation techniques needs further research. http://bit.ly/2Jn4v5a
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Introduction
In May 2019, the third European Respiratory Society research seminar of the Thoracic Oncology Assembly
entitled “New biomarkers, molecules and therapeutic sequences for non-small cell lung carcinoma
(NSCLC) in the era of precision medicine” was held in Paris, France. The previous two seminars of the
Thoracic Oncology Assembly were on targeted therapy (2015) [1] and immune checkpoint inhibitors (ICI,
2017) [2]. During this seminar, breakout sessions on difficult situations were organised. One of the most
original and useful was on the current challenges in brain metastases (BM) management, that we propose
to share with European Respiratory Journal readers.
BM are associated with decreased quality of life (QoL) and poorer survival compared to patients without
BM [3]. BM incidence is increasing, probably due to more screening, better imaging techniques and longer
survival because of improved systemic therapies, such as tyrosine kinase inhibitors (TKIs) and ICI (with or
without chemotherapy). Therefore, BM management becomes more and more important. However, BM
screening and treatment practices differ, partly because of heterogeneous access to imaging and
radiotherapy facilities, and heterogeneous access to newer systemic treatments [4]. Furthermore, guidelines
for BM management recommendations are not consensual (reviewed by LEVY et al. [4]), and high-level
evidence regarding screening and treatment is scarce. Randomised trials specifically including NSCLC BM
patients are largely lacking, and patients with untreated and/or unstable, or even all, BM were excluded
from most clinical trials (reviewed by EL RASSY et al. [5] and MCCOACH et al. [6]).
Screening
There was consensus that BM screening for NSCLC is useful, at least for certain stages. Most session
participants screened all stage III patients eligible for therapy with curative intent, and stage IV with a
targetable driver alteration, while some screened stage IB and II. Magnetic resonance imaging (MRI) was
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preferred above contrast-enhanced computed tomography (CT), but lack of timely access to MRI was a
problem. Brain CT during 18F-fluorodeoxyglucose positron emission tomography was sometimes used,
although the CT protocol was not optimised for brain imaging. Except for stage IV patients with a driver
alteration, regular brain imaging follow-up was not performed if a patient did not have baseline BM. Close
follow-up was usually performed if a systemic treatment was initiated in a patient with asymptomatic BM.
Selection for BM treatment
Prognostic scores (Recursive Partitioning Analysis (RPA) [7] and disease specific-Graded Prognostic
Assessment (ds-GPA) [8] were mainly used by radiation oncologists. A major drawback is that these
scores were validated in patients undergoing cranial irradiation (stereotactic (SRT) or whole brain
(WBRT)), but these scores did not incorporate the availability of a BM-effective systemic therapy. For
example, the molecular-GPA (mol-GPA) incorporates the presence of an epidermal growth factor receptor
(EGFR) or anaplastic lymphoma kinase (ALK) molecular alteration [9], but does not take into account
whether TKI treatment options are exhausted or not. Recently, ds-GPA was associated with survival in a
retrospective evaluation of 255 NSCLC BM patients treated with ICI [10]. There was consensus that
performance status was a major treatment selection factor, treatment being often withheld in front of poor
performance status, except in those with a targetable driver.
Selection of type of treatment
Local therapy (radiation and/or surgery) was preferred in neurologically symptomatic BM patients,
although upfront TKI with good blood–brain barrier (BBB) penetration rate was discussed in patients with
only mild symptoms, and without eloquent BM (i.e. growth of BM in these brain areas will result in loss
of sensory processing or linguistic ability, minor paralysis, or paralysis). In asymptomatic patients, ICI
and/or chemotherapy was preferred to WBRT, because of WBRT side-effects. It is known that for
neurologically asymptomatic NSCLC patients treated with first line chemotherapy, WBRT can be delayed
or withheld in more than half of patients (reviewed by ZIMMERMANN et al. [11]). ICI can also be used
upfront to treat selected asymptomatic BM patients, as was shown in a phase II trial. Objective response
rate was similar in BM and extracranial disease, around 30% for programmed death ligand-1 (PD-L1)
positive patients (10/34) but 0% (0/5) in PD-L1 negative/unevaluable patients (although some experienced
a long disease control) [12, 13]. Some participants specifically selected a first line ICI-chemotherapy
combination, even in PD-L1 ⩾50% patients, to minimise the risk of symptomatic BM progression.
Furthermore, the combination of ICI (pembrolizumab) and pemetrexed-platinum was superior to
platinum-doublet chemotherapy in an exploratory analysis of the KEYNOTE189 trial BM subgroup [14].
TABLE 1 Summary of breakthrough session and future directions
Topic discussed in
breakout session
Summary management from breakout session Future directions/open questions
Screening for BM Especially in stage III
Stage IV with driver alterations
No consensus on stage IB/II
MRI preferred
Follow-up only in BM and driver altered patients
Evaluate whether screening improves QoL and OS
Improved prediction models for risk of BM development needed
Improved imaging techniques needed
Selection for BM
treatment
Prognostic scores mainly used by radiation oncologist
Prognostic scores do not consider available systemic
treatment options
Performance status important for treatment selection
Evaluate prognostic scores incorporating whether there are
systemic treatment options available with intracranial activity
Selection of
treatment type
Preferably local treatment in neurologically
symptomatic patients
Systemic treatment in neurologically asymptomatic
patients preferred above WBRT; discussion on SRT
No consensus on treatment sequence in driver
mutated patients (SRT upfront versus TKI upfront)
If available, next generation TKIs preferred in driver
altered patients
No consensus on concurrent TKI and cranial
irradiation
Specific trials for BM patients evaluating systemic treatment
combinations (e.g. ICI plus chemotherapy, and/or
angiogenesis inhibition)
Evaluate best treatment strategy in randomised trials (SRT
followed by systemic treatment and vice versa)
Evaluate safety of concurrent TKI and cranial irradiation
BM: brain metastases; MRI: magnetic resonance imaging; QoL: quality of life; OS: overall survival; WBRT: whole brain irradiation; SRT:
stereotactic radiotherapy; TKI: tyrosine kinase inhibitor; ICI: immune checkpoint inhibitor.
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Although not evaluated in a randomised trial, bevacizumab added to carboplatin-paclitaxel was mentioned
as an option, based on the single arm phase II BRAIN trial (N=67) results, with a 61% intracranial
objective response rate and a median survival of 16.0 months [15]. Furthermore, in preclinical models,
bevacizumab reduces BM formation [16]. Unfortunately, BM subgroup results have not been reported for
the IMPOWER 150 trial quadruplet regimen (carboplatin-paclitaxel-bevacizumab-atezolizumab) [17].
There was no consensus on the treatment sequence (SRT followed by TKI or vice versa), especially for
neurologically asymptomatic EGFR-mutated patients. For EGFR, the discussion was mainly based on the
retrospective series described by MAGNUSON et al. [18], in which EGFR-mutated patients with BM had a
longer survival if treated upfront with SRT or WBRT, followed by EGFR-TKI, compared with upfront
EGFR-TKI followed by cranial irradiation upon brain progression. For driver mutated patients there was a
preference for the upfront use of next generation TKIs, such as osimertinib (EGFR) and alectinib/
brigatinib (ALK), as these drugs have a superior BBB penetration rate compared with first generation TKI.
Some participants used a TKI or ICI concurrent with cranial irradiation, to minimise the risk of a disease
flare (TKI) or to promote an abscopal effect (ICI). For those that did not use concurrent
radiation-systemic treatment strategies, the risk of increased neurotoxicity was the main concern.
Future directions
BM management practices discussed in this breakout session generally reflected the results reported in a
recent European survey [4]. Table 1 summarises the conclusions from the breakout sessions and open
questions/areas for future research.
BM screening: patients and techniques
For imaging, the main differences were that in the survey only two-thirds of stage III NSCLC and 50% of
driver altered patients were screened for BM, and only half of responders used MRI as the screening
method [4]. However, in stage III NSCLC (with a risk of approximately 20% asymptomatic baseline BM
[19]), MRI detects BM in 4.7% of neurologically asymptomatic patients, after a negative contrast-enhanced
brain CT [20]. Open questions are whether BM screening improves QoL and/or survival and which stages
should be screened. Besides a higher disease stage, adenocarcinoma histology, younger age and probably
ALK-rearrangements are associated with a higher risk of BM [21–23], but these factors are not sensitive
enough to select patients for baseline and/or follow-up BM screening. Up till now, blood or tissue-based
biomarkers (reviewed by PEDROSA et al. [24]) are not well enough studied, and more research is needed.
Another option could be to improve current imaging techniques.
Optimising systemic treatment for BM
As discussed during the breakthrough session, the combinations of different systemic treatments are
interesting to specifically evaluate in NSCLC BM patients, and specific trials for NSCLC patients with BM
are ongoing. Examples are ICI and chemotherapy (e.g. NCT03526900 (ATEZO-BRAIN: atezolizumab-
carboplatin-pemetrexed) or chemotherapy and bevacizumab (e.g. NCT01951482: pemetrexed-cisplatin
with/without bevacizumab), or TKI and bevacizumab (e.g. NCT02521051: alectinib plus bevacizumab, and
NCT02971501: osimertinib with/without bevacizumab).
Best sequence of local and systemic therapy
It is unclear whether upfront local therapy (especially SRT) followed by systemic treatment, or systemic
treatment followed by local therapy upon brain progression is the best treatment strategy for patients with
a driver alteration. The next generation TKIs have a good BBB penetration rate, with long BM control
reported in randomised phase III trials (reviewed by REMON et al. [22]). To answer this question, clinical
trials such as NCT03769103 (osimertinib versus SRT followed by osimertinib) and NCT02714010
(EGFR-TKI or EGFR-TKI concurrent with WBRT) are ongoing. Interestingly, ICI can result in dissociated
brain and extracranial responses [12]. A possible explanation for brain progression with extracranial
response is that the brain seems to have a different immune environment. Compared with the extracranial
disease sites BM more often have an immune ignorant phenotype [25] and a contraction in the number of
T-cell clones despite a higher tumour mutational burden [26]. With these data, the finding that radiation
can cause an abscopal effect [27], and the suggestion in retrospective series that ICI concurrent with SRT
can improve survival [28], the added value of cranial radiotherapy to ICI is being evaluated. Several
ICI-radiotherapy trials are ongoing (e.g. NCT02858869, NCT02696993, NCT02978404, NCT02696993,
NCT03955198).
There is a lack of good quality data on the safety of combining ICI or TKI with cranial irradiation. For the
EGFR-TKI erlotinib, gefitinib and icotinib phase II or III data have been reported, and the combination
with WBRT seems safe, but not when also combined with SRT (reviewed by HENDRIKS et al. [29]). A
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drawback is that in the majority of these trials there was no neurocognitive assessment, and there was no
selection based on EGFR-mutation [29]. Retrospective series suggest that PD-(L)1 inhibitors can be safely
combined with cranial irradiation, but detailed neurotoxicity assessment was lacking [30, 31]. To evaluate the
question whether TKI can be combined with cranial irradiation, a prospective observational Swiss registry
(TOaSTT: any type of systemic treatment) and a Dutch multicentre platform trial (NL6518/NTR6707, TKI
treatment) are currently enrolling patients; for ICI, several trials are ongoing (summarised above).
Conclusions
In conclusion, BM remain a major problem in NSCLC either at diagnosis or during the disease course.
Major improvements in systemic therapies have been observed during the past decade (TKI, ICI) but their
impact on BM control as well as their combination with radiation techniques (WBRT, SRT) needs further
research.
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